Microbial resistance and the Infectious Diseases Society of America (IDSA) guidelines

International Journal of Hematology

Volumn 68, Issue SUPPL. 1, 1998, Pages

  Feld, Ronald ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; CEFTAZIDIME; CLAVULANIC ACID; GLYCOPEPTIDE; TICARCILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CATHETER INFECTION; CONFERENCE PAPER; DISEASE DURATION; DRUG INDICATION; FEVER; GRAM POSITIVE BACTERIUM; HUMAN; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; TREATMENT OUTCOME;

DRUG RESISTANCE, MICROBIAL; FEVER; HUMANS; INFECTION CONTROL; NEUTROPENIA; UNITED STATES;

EID: 0031794072     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Shenep JL et al. Vancomycin, Ticarcillin and Amikacin Compared with Ticarcillin-Clavulanate and Amikacin in the Empirical Treatment of Febrile, Neutropenic Children with Cancer. N Engl J Med 1988;319:1053-1058.
2. Pico JL et al. Should Vancomycin be Used in Febrile Patients with Prolonged and Profound Neutropenia? Results of a Randomized Trial. Eur J Med 1993;2:275-280.
3. Ramphal R et al. Vancomycin is not an Essential Component of the Initial Empiric Treatment Regimen for Febrile Neutropenic Patients Receiving Ceftazidime: A Randomized Prospective Study. Antimicrob Agents Chemother 1992;36:1062-1067.
4. EORTC-National Cancer Institute of Canada. Vancomycin added to Empirical Combination Antibiotic Therapy for Fever in Granulocytopenic Cancer Patients. J Infect Dis 1991;163:951-958.